Drug Interactions in GLP-1 Research

# Introduction Glucagon-like peptide-1 (GLP-1) is a naturally occurring peptide hormone released from the gut in response to food intake. It plays a critical role in glucose homeostasis by stimulating insulin secretion, inhibiting glucagon release, and delaying gastric emptying [2]. Therapeutic agents that mimic the actions of GLP-1, known as GLP-1 receptor agonists (GLP-1RAs), have emerged as transformative approaches for managing type-2 diabetes and obesity [2]. This review focuses on the potential drug interactions in GLP-1 research, a topic of increasing importance given the widespread use of these medications. # Preclinical Research Several preclinical studies have shed light on potential drug interactions involving GLP-1RAs. For instance, the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide has been found to interact unintentionally with β-adrenoceptors in hyperglycemic or senescent cardiac cells, influencing glucose metabolism [5]. In silico investigations have also contributed valuable insights. Computational studies of albumin-GLP-1 receptor agonist complexes have been conducted to facilitate the design of more effective and safer diabetes drugs [4]. Phytochemicals have also demonstrated potential interactions with GLP-1RAs. Loureirin B, a compound found in the resin of Dracaena cochinchinensis, has been shown to have insulin-promoting effects similar to a GLP-1RA [7]. Furthermore, the compound 4-hydroxyisoleucine derived from fenugreek seeds has demonstrated neuroprotective effects in a rat model of demyelination by restoring insulin-like growth factor 1 (IGF-1) and GLP-1 levels [9]. # Clinical Evidence GLP-1RAs have been implicated in several clinical scenarios beyond diabetes and obesity. For example, they have been suggested as potential therapeutic agents in inflammatory bowel disease (IBD), given the link between GLP-1RAs and inflammatory pathways [1]. GLP-1RAs may also interact with drugs used in alcohol and substance use disorders, with emerging evidence supporting their potential role in these conditions [6]. However, further research is needed to clarify these interactions and their clinical implications. A risk assessment study using a federated research network revealed an association between GLP-1RA initiation and all-cause mortality as well as pancreatic events in people with obesity or type 2 diabetes [3]. This emphasizes the need for a careful consideration of the risk-benefit ratio when initiating GLP-1RAs. # Safety and Limitations While GLP-1RAs offer considerable promise, safety considerations and limitations must be taken into account. For instance, a pharmacovigilance study identified potential associations between GLP-1RAs and depressive disorders, underscoring the need for careful monitoring of mental health in patients receiving these medications [8]. Furthermore, the gut microbiota, which plays a significant role in metabolic regulation, may be affected by GLP-1RAs and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) [10]. This could potentially alter the efficacy and safety profile of these drugs, though more research is needed to confirm this hypothesis and understand its implications. # Key Takeaways GLP-1RAs represent a significant advance in the treatment of type 2 diabetes and obesity. However, their interactions with other drugs and physiological systems are complex and, in many cases, not fully understood. Future research should aim to clarify these interactions to optimize the safety and efficacy of GLP-1RAs. It is also important for clinicians to be aware of potential drug interactions when prescribing these medications, in order to provide the best possible care for their patients.